Cat. No.: HY-106312A

Enviroxime

Name: Enviroxime
Brand: MedChemExpress
SKU: HY-106312A
Price: 200.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: LY122772)

Avis client

Based on 1 Customer Validation

Enviroxime (LY122772) is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses. Enviroxime blocks the replication of plus-strand viral RNA by targeting the viral 3A coding region. Enviroxime can be a useful tool for investigating the natural function of the 3A protein.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 98.0%
CAS No.: 72301-79-2
Formule: C₁₇H₁₈N₄O₃S
Masse moléculaire:358.41

Stockage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Enviroxime Chemical Structure

CAS No.: 72301-79-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	IC₅₀	0.02 μg/mL Compound: 1	Antiviral activity against Poliovirus (PV-1) using plaque reduction assay using BSC1 cells Antiviral activity against Poliovirus (PV-1) using plaque reduction assay using BSC1 cells	[PMID: 9341923]
CV-1	ED₅₀	275 μg/mL Compound: Enviroxime2	Compound was evaluated for chemotherapeutic index in CV-1 cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose) Compound was evaluated for chemotherapeutic index in CV-1 cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose)	[PMID: 3005577]
CV-1	ED₅₀	8.8 μg/mL Compound: Enviroxime2	Antiviral activity against poliovirus type 1 in CV-1 cells Antiviral activity against poliovirus type 1 in CV-1 cells	[PMID: 3005577]
H1-HeLa	CC₅₀	16.76 μM Compound: Enviroxime	Cytotoxicity against human H1-HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human H1-HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 39032404]
H1-HeLa	CC₅₀	9.9 μM Compound: Enviroxime	Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay	[PMID: 38389877]
H1-HeLa	IC₅₀	41 μM Compound: Enviroxime	Cytotoxicity against human H1-HeLa cells transfected with EV71 replicon measured after 8 hrs by MTT assay Cytotoxicity against human H1-HeLa cells transfected with EV71 replicon measured after 8 hrs by MTT assay	[PMID: 38389877]
HeLa	ED₅₀	5.1 μg/mL Compound: Enviroxime2	Antiviral activity against rhinovirus type 10 in Hela cells Antiviral activity against rhinovirus type 10 in Hela cells	[PMID: 3005577]
HeLa	IC₅₀	0.04 μg/mL Compound: 1	Antiviral activity against Rhinovirus (RV-14) in HeLa cells using CPE/XTT assay Antiviral activity against Rhinovirus (RV-14) in HeLa cells using CPE/XTT assay	[PMID: 9341923]
HeLa	IC₅₀	0.04 μg/mL Compound: 1	Antiviral activity against Rhinovirus (RV-16) in HeLa cells using CPE/XTT assay Antiviral activity against Rhinovirus (RV-16) in HeLa cells using CPE/XTT assay	[PMID: 9341923]
HeLa	IC₅₀	0.05 μg/mL Compound: 1	Antiviral activity against Coxsackie virus (CoxA21) in HeLa cells using CPE/XTT assay Antiviral activity against Coxsackie virus (CoxA21) in HeLa cells using CPE/XTT assay	[PMID: 9341923]
HeLa	IC₅₀	0.06 μg/mL Compound: 1	Antiviral activity against Poliovirus (PV-1) in HeLa cells using CPE/XTT assay Antiviral activity against Poliovirus (PV-1) in HeLa cells using CPE/XTT assay	[PMID: 9341923]
HeLa	IC₅₀	0.07 μg/mL Compound: 1	Antiviral activity against Rhinovirus (RV-2) in HeLa cells using CPE/XTT assay Antiviral activity against Rhinovirus (RV-2) in HeLa cells using CPE/XTT assay	[PMID: 9341923]
Huh-7	CC₅₀	25 μM Compound: 93	Cytotoxicity against human Huh-7 cells Cytotoxicity against human Huh-7 cells	[PMID: 33539089]
KB	CC₅₀	2 μg/mL Compound: Enviroxime	Cellular toxicity in KB cells Cellular toxicity in KB cells	[PMID: 12852746]
RD	CC₅₀	>223.21 μM Compound: 1	Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
RD	CC₅₀	1.5 μM Compound: Enviroxime	Cytotoxicity against human RD cells by neutral red uptake assay Cytotoxicity against human RD cells by neutral red uptake assay	[PMID: 33031923]
RD	CC₅₀	10 μM Compound: Enviroxime	Cytotoxicity against human RD cells assessed as reduction in cell viability by visual analysis Cytotoxicity against human RD cells assessed as reduction in cell viability by visual analysis	[PMID: 37120998]
RD	CC₅₀	28 μM Compound: Enviroxime	Cytotoxicity against human RD cells infected with Enterovirus A71 assessed as reduction in cell viability measured by CCK-8 assay Cytotoxicity against human RD cells infected with Enterovirus A71 assessed as reduction in cell viability measured by CCK-8 assay	[PMID: 32619885]
RD	CC₅₀	36.4 μM Compound: Enviroxime	Cytotoxicity against human RD cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human RD cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 39032404]
RD	CC₅₀	4.2 μM Compound: Enviroxime	Cytotoxicity against human RD cells by microscopic based visual inspection method Cytotoxicity against human RD cells by microscopic based visual inspection method	[PMID: 33031923]
RD	CC₅₀	5.5 μM Compound: Enviroxime	Cytotoxicity against human RD cells assessed as reduction in cell viability by neutral red dye based spectrophotometric analysis Cytotoxicity against human RD cells assessed as reduction in cell viability by neutral red dye based spectrophotometric analysis	[PMID: 37120998]
RD	EC₅₀	0.24 μM Compound: 1	Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	CC₅₀	>100 μM Compound: 2	Cytotoxicity against African green monkey Vero cells after 3 days by spectrophotometry based MTS/PMS assay Cytotoxicity against African green monkey Vero cells after 3 days by spectrophotometry based MTS/PMS assay	[PMID: 22305341]
Vero	CC₅₀	>100 μM Compound: 59	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	[PMID: 19924996]
Vero	CC₅₀	>223.21 μM Compound: 1	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	>186 μM Compound: 1	Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells by after 24 to 36 hrs MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells by after 24 to 36 hrs MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	0.026 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.027 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.027 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.028 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.029 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.033 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.038 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.04 μM Compound: Enviroxime	Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.042 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.06 μM Compound: Enviroxime	Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.1 μM Compound: 1	Antiviral activity against Human coxsackievirus B6 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B6 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	0.1 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.11 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.11 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.11 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.12 μM Compound: 1	Antiviral activity against Human coxsackievirus B5 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B5 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	0.12 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.14 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.15 μM Compound: 1	Antiviral activity against Human coxsackievirus B2 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B2 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	0.15 μM Compound: 1	Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	0.15 μM Compound: Enviroxime	Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.19 μM Compound: Enviroxime	Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.25 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.48 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.5 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	0.7 μM Compound: 2	Antiviral activity against Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay Antiviral activity against Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay	[PMID: 22305341]
Vero	EC₅₀	0.7 μM Compound: 59	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 19924996]
Vero	EC₅₀	0.7 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	0.72 μM Compound: Enviroxime	Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	0.75 μM Compound: 1	Antiviral activity against Human coxsackievirus B1 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B1 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]
Vero	EC₅₀	1.3 μM Compound: 2	Antiviral activity against drug-resistant Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay Antiviral activity against drug-resistant Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay	[PMID: 22305341]
Vero	EC₅₀	1.5 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	1.7 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	1.8 μM Compound: Enviroxime	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	[PMID: 19237651]
Vero	EC₅₀	1.9 μM Compound: Enviroxime	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	[PMID: 19237651]
Vero	EC₅₀	2.48 μM Compound: 1	Antiviral activity against Human coxsackievirus B3 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay Antiviral activity against Human coxsackievirus B3 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	[PMID: 26885567]

Chemical Information

CAS No. 72301-79-2
Appearance Solid
Masse moléculaire 358.41
Formule C₁₇H₁₈N₄O₃S
Color White to off-white
SMILES

CC(C)S(=O)(N1C2=CC(/C(C3=CC=CC=C3)=N/O)=CC=C2N=C1N)=O
Synonyms

LY122772
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvant et solubilité

In Vitro:

DMSO : ≥ 50 mg/mL (139.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7901 mL

13.9505 mL

27.9010 mL

5 mM

0.5580 mL

2.7901 mL

5.5802 mL

10 mM

0.2790 mL

1.3951 mL

2.7901 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Heinz BA, et al. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995 Jul;69(7):4189-97. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7901 mL	13.9505 mL	27.9010 mL	69.7525 mL
	5 mM	0.5580 mL	2.7901 mL	5.5802 mL	13.9505 mL
	10 mM	0.2790 mL	1.3951 mL	2.7901 mL	6.9753 mL
	15 mM	0.1860 mL	0.9300 mL	1.8601 mL	4.6502 mL
	20 mM	0.1395 mL	0.6975 mL	1.3951 mL	3.4876 mL
	25 mM	0.1116 mL	0.5580 mL	1.1160 mL	2.7901 mL
	30 mM	0.0930 mL	0.4650 mL	0.9300 mL	2.3251 mL
	40 mM	0.0698 mL	0.3488 mL	0.6975 mL	1.7438 mL
	50 mM	0.0558 mL	0.2790 mL	0.5580 mL	1.3951 mL
	60 mM	0.0465 mL	0.2325 mL	0.4650 mL	1.1625 mL
	80 mM	0.0349 mL	0.1744 mL	0.3488 mL	0.8719 mL
	100 mM	0.0279 mL	0.1395 mL	0.2790 mL	0.6975 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Enviroxime